MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Edwards Lifesciences Corporation Net Debt 2011-2026 | EW
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.32 B | -2.42 B | -528 M | -151 M | -242 M | -561 M | -247 M | 122 M | 218 M | 233 M | 388 M | 729 M | 689 M | 88.9 M | 258 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 729 M | -2.42 B | -249 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 9.13 | -0.76 % | $ 327 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 9.38 | -1.78 % | $ 722 M | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
Inogen
INGN
|
-86.3 M | $ 6.5 | 1.25 % | $ 173 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.35 | 1.89 % | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
-52.1 M | $ 98.74 | -2.99 % | $ 1.26 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 16.35 | 0.74 % | $ 384 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
LENSAR
LNSR
|
-13.6 M | $ 5.52 | -1.08 % | $ 63.6 M | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 36.64 | -1.19 % | $ 1.14 B | USA |
 |
Medtronic PLC
MDT
|
23.6 B | $ 87.67 | -0.24 % | $ 113 B | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
NanoVibronix
NAOV
|
-636 K | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
-10.5 M | $ 24.45 | -0.85 % | $ 207 M | USA |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
Orthofix Medical
OFIX
|
78.5 M | $ 11.79 | -1.17 % | $ 467 M |  Curacao |
 |
Outset Medical
OM
|
63 M | $ 3.52 | -0.28 % | $ 53.5 K | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.6 | -10.61 % | $ 32.7 M | USA |
 |
Aethlon Medical
AEMD
|
-4.85 M | $ 2.27 | -2.16 % | $ 3.54 M | USA |
 |
PAVmed
PAVM
|
-15.1 M | $ 8.94 | -3.87 % | $ 64.7 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
LivaNova PLC
LIVN
|
-282 M | $ 63.65 | 0.55 % | $ 3.47 B |  Britain |
 |
InspireMD
NSPR
|
-5.65 M | $ 1.73 | -2.26 % | $ 111 M | Israel |
 |
Insulet Corporation
PODD
|
468 M | $ 218.11 | 0.98 % | $ 15.3 B | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 11.41 | 0.18 % | $ 1.54 B | USA |
 |
Quanterix Corporation
QTRX
|
7.4 M | $ 3.9 | -1.52 % | $ 166 M | USA |
 |
Penumbra
PEN
|
-152 M | $ 336.42 | 0.04 % | $ 13.1 B | USA |
 |
MiMedx Group
MDXG
|
-148 M | $ 3.94 | -3.9 % | $ 582 M | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
-12.8 M | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
-4.79 M | $ 0.68 | -2.2 % | $ 28.5 M | USA |
 |
Inspire Medical Systems
INSP
|
-433 M | $ 50.45 | -1.87 % | $ 1.48 B | USA |